Lexaria Bioscience (LEXX) Stock Forecast: StockMap's 2-Week Call
LEXX stock forecast: StockMap's model calls Lexaria Bioscience Strong Underperform for the two weeks after the Nov 19 close: it expects LEXX to trail the growth index. It is a call on the gap, not a price target. Right in 4 of 6 two-week windows on LEXX since Aug 21; by chance, a call on the same dates was right 59% of the time.
Lexaria Bioscience last closed at $4.49, +4.91% on the session.
Against the IVW growth benchmark the position is +7.24% over the forecast window.
Lexaria Bioscience's market cap is $9.46M as of November 19, 2026.
Calls down ↘: the model's call · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -51 (behind).
Where LEXX sits: sized by market cap, coloured by the day's move.
The read is built from 15 underlying insights — 4 bullish and 11 bearish.
Agreement across those insights is 73%.
49 daily calls for LEXX so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
Lexaria Bioscience is classified under Health Care / Pharmaceuticals.
StockMap tracks Lexaria Bioscience as the 131st largest of the 153 companies it covers in the Pharmaceuticals industry, part of the Health Care sector.
Across that group the current two-week reads are 80 Moderate Underperform, 44 Neutral and 29 Strong Underperform.
On that composite Lexaria Bioscience ranks 127th of 153 in the group, against a group median of -0.36.